Skip to main content

Andrea Berry, MD

Academic Title:

Assistant Professor

Primary Appointment:

Pediatrics

Secondary Appointment(s):

Medicine

Location:

HSF-II, 480

Phone (Primary):

(410) 706-1123

Phone (Secondary):

(410) 706-5328

Fax:

(410) 706-6205

Education and Training

Columbia College, B.A., Biochemistry, 1998

University of Pennsylvania School of Medicine, M.D., 2003

Residency, The Children's Hospital of Philadelphia, Pediatrics, 2003-2006

Fellowship, University of Maryland School of Medicine, Pediatric Infectious Diseases, 2006-2009

Biosketch

Dr. Berry is a board-certified pediatric infectious disease specialist with an interest in malaria immunology and pediatric vaccine trials. She co-leads the Immunoepidemiology and Pathogenesis Unit within the Malaria Research Program, where she studies the humoral immune response to malaria following natural infection and malaria vaccination. Dr. Berry conducts malaria vaccine trials and challenge studies at the University of Maryland Center for Vaccine Development and Global Health (CVD).

Dr. Berry is a member of the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine and Treatment Evaluation Unit (VTEU) network of investigators. Recent NIAID clinical studies have included trials of pandemic and seasonal influenza vaccines, a study of concurrent use of both licensed brands of rotavirus vaccines within the same schedule, and a study of the immunogenicity of Human Papilloma Virus vaccine when given outside of the recommended schedule.

Research/Clinical Keywords

Malaria, clinical vaccine trials, immunology.

Highlighted Publications

Ishizuka AS, Lyke KE, DeZure A, Berry AA, Richie TL, Mendoza FH, Enama ME, Gordon IJ, Chang LJ, Sarwar UN, Zephir KL, Holman LA, James ER, Billingsley PF, Gunasekera A, Chakravarty S, Manoj A, Li M, Ruben AJ, Li T, Eappen AG, Stafford RE, K C N, Murshedkar T, DeCederfelt H, Plummer SH, Hendel CS, Novik L, Costner PJ, Saunders JG, Laurens MB, Plowe CV, Flynn B, Whalen WR, Todd JP, Noor J, Rao S, Sierra-Davidson K, Lynn GM, Epstein JE, Kemp MA, Fahle GA, Mikolajczak SA, Fishbaugher M, Sack BK, Kappe SH, Davidson SA, Garver LS, Björkström NK, Nason MC, Graham BS, Roederer M, Sim BK, Hoffman SL, Ledgerwood JE, Seder RA. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med. 2016 May 9;22:614–623.

Travassos MA, Coulibaly D, Bailey JA, Niangaly A, Adams M, Nyunt MM, Ouattara A, Lyke KE, Laurens MB, Pablo J, Jasinskas A, Nakajima-Sasaki R, Berry AA, Takala-Harrison S, Kone AK, Kouriba B, Rowe JA, Doumbo OK, Thera MA, Laufer MK, Felgner PL, Plowe CV. Differential recognition of terminal extracellular Plasmodium falciparum VAR2CSA domains by Sera from multigravid, malaria-exposed Malian women. Am J Trop Med Hyg. 2015 April 27;92(6):1190-1194.

Bailey JA, Pablo J, Niangaly A, Travassos MA, Ouattara A, Coulbaly D, Laurens MB, Takala-Harrison SL, Lyke KE, Skinner J, Berry AA, Jasinskas A, Nakajima-Sasaki R, Kouriba B, Thera MA, Felgner PL, Doumbo OK, Plowe CV. Seroreactivity to a large panel of field-derived Plasmodium falciparum apical membrane antigen 1 and merozoite surface protein 1 variants reflects seasonal and lifetime acquired responses to malaria. Am J Trop Med Hyg, 2015 Jan:92(1):9-12.

Travassos MA, Niangaly A, Bailey JA, Ouattara A, Coulibaly D, Laurens MB, Pablo J, Jasinskas A, Nakajima-Sasaki R, Berry AA, Takala-Harrison S, Kouriba B, Rowe JA, Lyke KE, Doumbo OK, Thera MA, Felgner PL, Plowe CV. Seroreactivity to Plasmodium falciparum erythrocyte membrane protein 1 intracellular domain in malaria-exposed children and adults . Journal of Infectious Diseases. 2013;208(9):1514-1519.

Berry AA, Yang Y, Pakharukova N, Garnett JA, Lee W, Cota E, Marchant J, Roy S, Tuittila M, Liu B, Inman KG, Ruiz-Perez F, Mandomando I, Nataro JP, Zavialov AV, Matthews S. Structural insight into host recognition by aggregative adherence fimbriae of enteroaggregative Escherichia coli. PLoS Pathogens. 2014 Sep 18;10(9):e1004404.

Additional Publication Citations

Graves SF, Kouriba B, Diarra I, Daou M, Niangaly A, Coulibaly D, Keita Y, Laurens MB, Berry AA, Vekemans J, Ripley Ballou W, Lanar DE, Dutta S, Gray Heppner D, Soisson L, Diggs CL, Thera MA, Doumbo OK, Plowe CV, Sztein MB, Lyke KE. Strain-specific Plasmodium falciparum multifunctional CD4(+) T cell cytokine expression in Malian children immunized with the FMP2.1/AS02A vaccine candidate. Vaccine. 2016 May 17;34(23):2546-55.

Libster R, McNeal M, Walter EB, Shane AL, Winokur P, Cress G, Berry AA, Kotloff KL, Sarpong K, Turley CB, Harrison CJ, Pahud BA, Marbin J, Dunn J, El-Khorazaty J, Barrett J, Edwards KM; VTEU Rotavuris Vaccine Study Work Group. Safety and immunogenicity of sequential Rotavirus vaccine schedules. Pediatrics. 2016 Feb;137(2):1-10.

Jackson LA, Campbell JD, Frey SE, Edwards KE, Keitel WA, Kotloff KL, Berry AA, Graham I, Atmar RL, Creech CB, Thomsen IP, Patel SM, Gutierrez AF, Anderson EL, El Sahly HM, Hill H, Noah DL, Bellamy AR. Effect of varying doses of a monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on immune response: A randomized clinical trial. JAMA. 2015 Jul 21;314(3):237-46.

Halasa NB, Gerber MA, Berry AA, Anderson EL, Winokur P, Keyserling H, Eckard AR, Hill H, Wolff MC, McNeal MM, Edwards KM, Bernstein DI. Safety and immunogenicity of full-dose trivalent inactivated influenza vaccine (TIV) compared with half-dose TIV administered to children 6 through 35 months of age. J Ped Infect Dis. 2015 Sept;4(3):214-24.

Travassos MA, Coulibaly D, Laurens MB, Dembele A, Tolo Y, Traore K, Niangaly A, Guindo A, Wu Y, Berry AA, Jacob CG, Takala-Harrison S, Adams M, Shrestha B, Wu AZ, Kouriba B, Lyke KE, Diallo DA, Doumbo OK, Plowe CV, Thera MA. Hemoglobin C trait provides protection from clinical falciparum malaria in Malian children. J Infect Dis. 2015 May 27.

Gandhi K, Thera MA, Coulibaly D, Traoré K, Guindo AB, Ouattara A, Takala-Harrison S, Berry AA, Doumbo OK, Plowe CV. Variation in the circumsporozoite protein of Plasmodium falciparum: Vaccine development implications. PLoS One. 2014 Jul 3;9(7):e101783. doi: 10.1371/journal.pone.0101783.

Murphy SC, Hermsen CC, Douglas AD, Edwards NJ, Petersen I, Fahle GA, Adams M, Berry AA, Billman ZP, Gilbert SC, Laurens MB, Leroy O, Lyke KE, Plowe CV, Seilie AM, Strauss KA, Teelen K, Hill AV, Sauerwein RW. External quality assurance of malaria nucleic acid testing for clinical trials and eradication surveillance. PLOS One. 2014 May 16;9(5):e97398.

Yang Y, Berry AA, Lee W-C, GarnettJA, MarchantJ, LevineJA, SimpsonPJ, FogelSA, VarneyKM, MatthewsSJ, NataroJP, and InmanKG. Complete 1H, 13C and 15N NMR assignments for donor‑strand complemented AafA, the major pilin of aggregative adherence fimbriae (AAF/II) from enteroaggregative E. coli. Biomol NMR Assign. 2011 Apr;5(1):1-5.

Berry SA, Johns B, Shih C, Berry AA, Walker DG. The cost‑effectiveness of rotavirus vaccination in Malawi. J Infect Dis. 2010;202:S108-15. PMC3962285

Chow AA, Moser CA, Speaker TJ, Offit PA. Determination of efficiency of attachment of biotinylated antibodies to avidin-linked, aqueous-based microcapsules by flow cytometry. J Immunol Methods. 2003;277:135-139.

Research Interests

Dr. Berry studies the humoral immune response to malaria following natural infection and malaria vaccination. She uses protein and peptide microarrays to simultaneously profile the antibody reactivity to hundreds to thousands of malaria proteins and peptides. Her goal is to identify signatures of antibody responses that are associated with protection from malaria illness in order to inform the design of next generation malaria vaccines.

Dr. Berry is a member of the National National Institute of Allergy and Infectious Diseases (NIAID) Vaccine and Treatment Evaluation Unit (VTEU) network of investigators. Recent NIAID clinical studies have included trials of pandemic and seasonal influenza vaccines, a study of concurrent use of both licensed brands of rotavirus vaccines within the same schedule, and a study of the immunogenicity of Human Papilloma Virus vaccine when given outside of the recommended schedule.

Clinical Specialty Details

Dr. Berry is a board-certified pediatric infectious disease specialist. She attends on the pediatric infectious disease consult service, where she also teaches medical students, residents, and fellows. In addition, she provides pre-travel consultations at the University of Marlyand School of Medicine Traveler's Health Clinic.

Awards and Affiliations

2016: University of Maryland School of Medicine Passano Foundation Clinician-Investigator Award

Grants and Contracts

Grants

Christopher Plowe, M.D., M.P.H., F.A.S.T.M.H (PI)
Role: Co-Investigator
R01 AI093635-01A1
2/2/2012–1/31/2016
National Institutes of Health (NIH)/NIAID
Immuno-epidemiological Epitope Mapping of a Blood Stage Malaria Vaccine Antigen

Contracts

Dr. Berry works on numerous contracts; a select number are included below. Please refer to her CV for a full listing.

Andrea Berry, M.D. (PI)
2014-present
NIH
Phase II Open-Label Study in Healthy Pediatric Populations to Assess the Safety, Reactogenicity, and Immunogenicity of an Intramuscular Unadjuvanted Subvirion Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine

Andrea Berry, M.D. (PI)
2014-present
GlaxoSmithKline
Safety and Immunogenicity Study of GSK Biologicals’ MMR Vaccine (209762)(Priorix®) Compared to Merc & Co., Inc.’s MMR vaccine (M-M-R®II or VaxPro), as a first dose, both co-administered with Varivax, Havrix (all subjects) and Prevnar 13 (US subset) in Healthy Children 12 to 15 Months of Age

Andrea Berry, M.D. (PI)
2014-present
Novartis
A phase III, Stratified, Randomized, Observer Blind, Controlled, Multicenter Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children >6 to <72 Months of Age

Andrea Berry, M.D. (PI)
2013-present
GlaxoSmithKline
Immunogenicity and Safety Study of GSK Biologicals’ Priorix® Vaccine at an End of Shelf-life Potency Compared to Merck & Co., Inc.’s MMR Vaccine when Both are Given on a 2-Dose Schedule to Healthy Children in their 2nd Year of Life

Wilbur Chen, M.D., M.S. (PI)
Role: Co-Investigator
2012-present
NIH
Longitudinal Study of Local and Systemic Immune Responses and Gut Microbiota in Children Who Have Received the Ty21a Typhoid Vaccine

Wilbur Chen, M.D., M.S. (PI)
Role: Sub-I
2010-present
NIH
Phase 1 Study of the Safety and Immunogenicity of Recombinant Staphylococcal Enterotoxin B Vaccine

Kirsten Lyke, M.D. (PI)
Role: Sub-I
2008-present
Sanaria, NIH
An Interventional Plasmodium falciparum Malaria Challenge Model Utilizing the NF54 Strain of Parasite Transmitted by Aseptic A. Stephensi Mosquitoes to Healthy Malaria-naïve Adult Volunteers

Christopher Plowe, M.D., M.P.H., F.A.S.T.M.H (PI)
Role: Sub-I
2008-present
NIH
Incidence of Malaria Infection and Disease at a Malaria Vaccine Testing Site in Bandiagara, Mali